Article

Immunogenicity and protective efficacy of one- and two-dose regimens of the Ad26.COV2.S COVID-19 vaccine candidate in adult and aged rhesus macaques

2020-11-17

Abstract excerpt

Safe and effective coronavirus disease (COVID)-19 vaccines are urgently needed to control the ongoing pandemic. While single-dose vaccine regimens would provide multiple advantages, two doses may improve the magnitude and durability of immunity and protective efficacy. We assessed one- and two-dose regimens of the Ad26.COV2.S vaccine candidate in adult and aged non-human primates (NHP). A two-dose Ad26.COV2.S regi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f3a3b3f8-28e3-595b-a93a-75d55f68c4e3
DOI: 10.1101/2020.11.17.368258

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Immunogenicity and protective efficacy of one- and two-dose regimens of the Ad26.COV2.S COVID-19 vaccine candidate in adult and aged rhesus macaquesDOI 10.1101/2020.11.17.368258Read

Efficacy and Safety of a Booster Regimen of Ad26.COV2.S Vaccine against Covid-19Semantic proximity Read

Dynamics of Temporal Immune Responses in Nonhuman Primates and Humans Immunized with COVID-19 VaccinesSemantic proximity Read

SARS-CoV-2 binding and neutralizing antibody levels after vaccination with Ad26.COV2.S predict durable protection in rhesus macaquesSemantic proximity Read

Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but not intranasally with a single dose of a recombinant vaccineSemantic proximity Read

Assessment of the efficacy of SARS-CoV-2 vaccines in non-human primate studies: a systematic reviewSemantic proximity Read

SARS-CoV-2 preS dTM vaccine booster candidates increase functional antibody responses and cross-neutralization against SARS-CoV-2 variants of concern in non-human primatesSemantic proximity Read

High efficacy of VLA2001 vaccine against SARS-CoV-2 infection in non-human primatesSemantic proximity Read

Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trialSemantic proximity Read

Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trialSemantic proximity Read

Protein Vaccine Induces a Durable, More Broadly Neutralizing Antibody Response in Macaques than Natural Infection with SARS-CoV-2 P.1Semantic proximity Read

Beta variant COVID-19 protein booster vaccines elicit durable cross-neutralization against SARS-CoV-2 variants of concern in non-human primatesSemantic proximity Read